Diabetic Retinopathy and Cardiovascular Disease: A Literature Review

References

• Klein BE. Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol. 2007;14(4):179–183. doi:10.1080/09286580701396720
   PubMed Web of Science ®Google Scholar
• Teo ZL, Tham YC, Yu M, et al. Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis. Ophthalmology. 2021;128(11):1580–1591. doi:10.1016/j.ophtha.2021.04.027
   PubMed Web of Science ®Google Scholar
• Collaborators GBDCo D. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1151–1210. doi:10.1016/S0140-6736(17)32152-9
   PubMed Web of Science ®Google Scholar
• Wilkinson CP, Ferris FL 3rd, Klein RE, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003;110(9):1677–1682. doi:10.1016/S0161-6420(03)00475-5
   PubMed Web of Science ®Google Scholar
• Alghadyan AA. Diabetic retinopathy - an update. Saudi J Ophthalmol. 2011;25(2):99–111. doi:10.1016/j.sjopt.2011.01.009
   PubMedGoogle Scholar
• Xie J, Ikram MK, Cotch MF, et al. Association of diabetic macular edema and proliferative diabetic retinopathy with cardiovascular disease: a systematic review and meta-analysis. JAMA Ophthalmol. 2017;135(6):586–593. doi:10.1001/jamaophthalmol.2017.0988
   PubMed Web of Science ®Google Scholar
• Rajala U, Pajunpaa H, Koskela P, Keinanen-Kiukaanniemi S. High cardiovascular disease mortality in subjects with visual impairment caused by diabetic retinopathy. Diabetes Care. 2000;23(7):957–961. doi:10.2337/diacare.23.7.957
   PubMed Web of Science ®Google Scholar
• Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54(6):1615–1625. doi:10.2337/diabetes.54.6.1615
   PubMed Web of Science ®Google Scholar
• Khalfaoui T, Lizard G, Ouertani-Meddeb A. Adhesion molecules (ICAM-1 and VCAM-1) and diabetic retinopathy in type 2 diabetes. J Mol Histol. 2008;39(2):243–249. doi:10.1007/s10735-007-9159-5
   PubMed Web of Science ®Google Scholar
• Kanter JE, Kramer F, Barnhart S, et al. Diabetes promotes an inflammatory macrophage phenotype and atherosclerosis through acyl-CoA synthetase 1. Proc Natl Acad Sci U S A. 2012;109(12):E715–E724. doi:10.1073/pnas.1111600109
   PubMed Web of Science ®Google Scholar
• Li JJ, Chen JL. Inflammation may be a bridge connecting hypertension and atherosclerosis. Med Hypotheses. 2005;64(5):925–929. doi:10.1016/j.mehy.2004.10.016
   PubMed Web of Science ®Google Scholar
• Skinner MK, Manikkam M, Guerrero-Bosagna C. Epigenetic transgenerational actions of environmental factors in disease etiology. Trends Endocrinol Metab. 2010;21(4):214–222. doi:10.1016/j.tem.2009.12.007
   PubMed Web of Science ®Google Scholar
• Devaskar SU, Raychaudhuri S. Epigenetics--a science of heritable biological adaptation. Pediatr Res. 2007;61(5 Pt 2):1R–4R. doi:10.1203/pdr.0b013e31805cdbd8
   PubMed Web of Science ®Google Scholar
• Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88–98. doi:10.1038/nrendo.2017.151
   PubMed Web of Science ®Google Scholar
• Liu Y, Yang J, Tao L, et al. Risk factors of diabetic retinopathy and sight-threatening diabetic retinopathy: a cross-sectional study of 13 473 patients with type 2 diabetes mellitus in mainland China. BMJ open. 2017;7(9):e016280. doi:10.1136/bmjopen-2017-016280
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–853. doi:10.1016/S0140-6736(98)07019-6
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. New Engl J Med. 2008;359(15):1577–1589. doi:10.1056/NEJMoa0806470
   PubMed Web of Science ®Google Scholar
• Strain WD, Paldánius PM. Diabetes, cardiovascular disease and the microcirculation. Cardiovasc Diabetol. 2018;17(1):57. doi:10.1186/s12933-018-0703-2
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317(7160):703–713. doi:10.1136/bmj.317.7160.703
   PubMed Web of Science ®Google Scholar
• Betteridge DJ. What is oxidative stress? Metabolism. 2000;49(2 Suppl 1):3–8. doi:10.1016/S0026-0495(00)80077-3
   PubMed Web of Science ®Google Scholar
• Hammes HP. Diabetic retinopathy: hyperglycaemia, oxidative stress and beyond. Diabetologia. 2018;61(1):29–38. doi:10.1007/s00125-017-4435-8
   PubMed Web of Science ®Google Scholar
• Kang Q, Yang C. Oxidative stress and diabetic retinopathy: molecular mechanisms, pathogenetic role and therapeutic implications. Redox Biol. 2020;37:101799. doi:10.1016/j.redox.2020.101799
   PubMed Web of Science ®Google Scholar
• Giacco F, Brownlee M, Schmidt AM. Oxidative stress and diabetic complications. Circ Res. 2010;107(9):1058–1070. doi:10.1161/CIRCRESAHA.110.223545
   PubMed Web of Science ®Google Scholar
• Munzel T, Daiber A, Ullrich V, Mulsch A. Vascular consequences of endothelial nitric oxide synthase uncoupling for the activity and expression of the soluble guanylyl cyclase and the cGMP-dependent protein kinase. Arterioscler Thromb Vasc Biol. 2005;25(8):1551–1557. doi:10.1161/01.ATV.0000168896.64927.bb
   PubMed Web of Science ®Google Scholar
• Rapoport RM, Draznin MB, Murad F. Endothelium-dependent relaxation in rat aorta may be mediated through cyclic GMP-dependent protein phosphorylation. Nature. 1983;306(5939):174–176. doi:10.1038/306174a0
   PubMed Web of Science ®Google Scholar
• Bassenge E. Antiplatelet effects of endothelium-derived relaxing factor and nitric oxide donors. Eur Heart J. 1991;12(Suppl E):12–15. doi:10.1093/eurheartj/12.suppl_E.12
   PubMedGoogle Scholar
• Steven S, Frenis K, Oelze M, et al. Vascular inflammation and oxidative stress: major triggers for cardiovascular disease. Oxid Med Cell Longev. 2019;2019:7092151. doi:10.1155/2019/7092151
   PubMed Web of Science ®Google Scholar
• Nakayama T. Prostacyclin synthase gene: genetic polymorphisms and prevention of some cardiovascular diseases. Curr Med Chem Cardiovasc Hematol Agents. 2005;3(2):157–164. doi:10.2174/1568016053544327
   PubMedGoogle Scholar
• Semeraro F, Morescalchi F, Cancarini A, Russo A, Rezzola S, Costagliola C. Diabetic retinopathy, a vascular and inflammatory disease: therapeutic implications. Diabetes Metab. 2019;45(6):517–527. doi:10.1016/j.diabet.2019.04.002
   PubMed Web of Science ®Google Scholar
• Aplin AC, Gelati M, Fogel E, Carnevale E, Nicosia RF. Angiopoietin-1 and vascular endothelial growth factor induce expression of inflammatory cytokines before angiogenesis. Physiol Genomics. 2006;27(1):20–28. doi:10.1152/physiolgenomics.00048.2006
   PubMed Web of Science ®Google Scholar
• Tabas I, Garcia-Cardena G, Owens GK. Recent insights into the cellular biology of atherosclerosis. J Cell Biol. 2015;209(1):13–22. doi:10.1083/jcb.201412052
   PubMed Web of Science ®Google Scholar
• Chistiakov DA, Melnichenko AA, Grechko AV, Myasoedova VA, Orekhov AN. Potential of anti-inflammatory agents for treatment of atherosclerosis. Exp Mol Pathol. 2018;104(2):114–124. doi:10.1016/j.yexmp.2018.01.008
   PubMed Web of Science ®Google Scholar
• Pirillo A, Norata GD, Catapano AL. LOX-1, OxLDL, and atherosclerosis. Mediators Inflamm. 2013;2013:152786. doi:10.1155/2013/152786
   PubMed Web of Science ®Google Scholar
• Libby P. Inflammation in atherosclerosis. Nature. 2002;420(6917):868–874. doi:10.1038/nature01323
   PubMed Web of Science ®Google Scholar
• Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation. 2001;104(3):365–372. doi:10.1161/01.CIR.104.3.365
   PubMed Web of Science ®Google Scholar
• Cheung N, Wong TY. Diabetic retinopathy and systemic vascular complications. Prog Retin Eye Res. 2008;27(2):161–176. doi:10.1016/j.preteyeres.2007.12.001
   PubMed Web of Science ®Google Scholar
• Kowluru RA, Kowluru A, Mishra M, Kumar B. Oxidative stress and epigenetic modifications in the pathogenesis of diabetic retinopathy. Prog Retin Eye Res. 2015;48:40–61. doi:10.1016/j.preteyeres.2015.05.001
   PubMed Web of Science ®Google Scholar
• Zhang Y, Sun Z, Jia J, et al. Overview of histone modification. Adv Exp Med Biol. 2021;1283:1–16.
   PubMed Web of Science ®Google Scholar
• Miranda TB, Jones PA. DNA methylation: the nuts and bolts of repression. J Cell Physiol. 2007;213(2):384–390. doi:10.1002/jcp.21224
   PubMed Web of Science ®Google Scholar
• Zheng J, Cheng J, Zhang Q, Xiao X. Novel insights into DNA methylation and its critical implications in diabetic vascular complications. Biosci Rep. 2017;37(2). doi:10.1042/BSR20160611
   Google Scholar
• Hiltunen MO, Turunen MP, Hakkinen TP, et al. DNA hypomethylation and methyltransferase expression in atherosclerotic lesions. Vasc Med. 2002;7(1):5–11. doi:10.1191/1358863x02vm418oa
   PubMed Web of Science ®Google Scholar
• Hiltunen MO, Yla-Herttuala S. DNA methylation, smooth muscle cells, and atherogenesis. Arterioscler Thromb Vasc Biol. 2003;23(10):1750–1753. doi:10.1161/01.ATV.0000092871.30563.41
   PubMed Web of Science ®Google Scholar
• Keating ST, Plutzky J, El-Osta A. Epigenetic changes in diabetes and cardiovascular risk. Circ Res. 2016;118(11):1706–1722. doi:10.1161/CIRCRESAHA.116.306819
   PubMed Web of Science ®Google Scholar
• Dunn J, Qiu H, Kim S, et al. Flow-dependent epigenetic DNA methylation regulates endothelial gene expression and atherosclerosis. J Clin Invest. 2014;124(7):3187–3199. doi:10.1172/JCI74792
   PubMed Web of Science ®Google Scholar
• Matouk CC, Marsden PA. Epigenetic regulation of vascular endothelial gene expression. Circ Res. 2008;102(8):873–887. doi:10.1161/CIRCRESAHA.107.171025
   PubMed Web of Science ®Google Scholar
• Zaina S, Lindholm MW, Lund G. Nutrition and aberrant DNA methylation patterns in atherosclerosis: more than just hyperhomocysteinemia? J Nutr. 2005;135(1):5–8. doi:10.1093/jn/135.1.5
   PubMed Web of Science ®Google Scholar
• Fuster JJ, MacLauchlan S, Zuriaga MA, et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science. 2017;355(6327):842–847. doi:10.1126/science.aag1381
   PubMed Web of Science ®Google Scholar
• Duraisamy AJ, Mishra M, Kowluru A, Kowluru RA. Epigenetics and regulation of oxidative stress in diabetic retinopathy. Invest Ophthalmol Vis Sci. 2018;59(12):4831–4840. doi:10.1167/iovs.18-24548
   PubMed Web of Science ®Google Scholar
• Chen H, Zhang X, Liao N, et al. Identification of NLRP3 inflammation-related gene promoter hypomethylation in diabetic retinopathy. Invest Ophthalmol Vis Sci. 2020;61(13):12. doi:10.1167/iovs.61.13.12
   Web of Science ®Google Scholar
• Berdasco M, Gomez A, Rubio MJ, et al. DNA methylomes reveal biological networks involved in human eye development, functions and associated disorders. Sci Rep. 2017;7(1):11762. doi:10.1038/s41598-017-12084-1
   PubMedGoogle Scholar
• Afanas’ev I. New nucleophilic mechanisms of ros-dependent epigenetic modifications: comparison of aging and cancer. Aging Dis. 2014;5(1):52–62. doi:10.14336/AD.2014.050052
   PubMed Web of Science ®Google Scholar
• Kowluru RA, Shan Y. Role of oxidative stress in epigenetic modification of MMP-9 promoter in the development of diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2017;255(5):955–962. doi:10.1007/s00417-017-3594-0
   PubMed Web of Science ®Google Scholar
• Di Y, Wang Y, Wang YX, Wang X, Ma Y, Nie QZ. Maternally expressed gene 3 regulates retinal neovascularization in retinopathy of prematurity. Neural Regen Res. 2022;17(6):1364–1368. doi:10.4103/1673-5374.327358
   PubMed Web of Science ®Google Scholar
• He Y, Dan Y, Gao X, Huang L, Lv H, Chen J. DNMT1-mediated lncRNA MEG3 methylation accelerates endothelial-mesenchymal transition in diabetic retinopathy through the PI3K/Akt/mTOR signaling pathway. Am J Physiol Endocrinol Metab. 2021;320(3):E598–E608. doi:10.1152/ajpendo.00089.2020
   PubMed Web of Science ®Google Scholar
• Chen J, Liao L, Xu H, Zhang Z, Zhang J. Long non-coding RNA MEG3 inhibits neovascularization in diabetic retinopathy by regulating microRNA miR-6720-5p and cytochrome B5 reductase 2. Bioengineered. 2021;12(2):11872–11884. doi:10.1080/21655979.2021.2000721
   PubMed Web of Science ®Google Scholar
• Ishii T, Furuya F, Takahashi K, et al. Angiopoietin-like protein 2 promotes the progression of diabetic kidney disease. J Clin Endocrinol Metab. 2019;104(1):172–180. doi:10.1210/jc.2017-02705
   PubMed Web of Science ®Google Scholar
• Bannister AJ, Kouzarides T. Regulation of chromatin by histone modifications. Cell Res. 2011;21(3):381–395. doi:10.1038/cr.2011.22
   PubMed Web of Science ®Google Scholar
• Reddy MA, Zhang E, Natarajan R. Epigenetic mechanisms in diabetic complications and metabolic memory. Diabetologia. 2015;58(3):443–455. doi:10.1007/s00125-014-3462-y
   PubMed Web of Science ®Google Scholar
• Liao Y, Gou L, Chen L, et al. NADPH oxidase 4 and endothelial nitric oxide synthase contribute to endothelial dysfunction mediated by histone methylations in metabolic memory. Free Radic Biol Med. 2018;115:383–394. doi:10.1016/j.freeradbiomed.2017.12.017
   PubMed Web of Science ®Google Scholar
• Alkemade FE, van Vliet P, Henneman P, et al. Prenatal exposure to apoE deficiency and postnatal hypercholesterolemia are associated with altered cell-specific lysine methyltransferase and histone methylation patterns in the vasculature. Am J Pathol. 2010;176(2):542–548. doi:10.2353/ajpath.2010.090031
   PubMed Web of Science ®Google Scholar
• Greissel A, Culmes M, Napieralski R, et al. Alternation of histone and DNA methylation in human atherosclerotic carotid plaques. Thromb Haemost. 2015;114(2):390–402. doi:10.1160/TH14-10-0852
   PubMed Web of Science ®Google Scholar
• Wierda RJ, Rietveld IM, van Eggermond MC, et al. Global histone H3 lysine 27 triple methylation levels are reduced in vessels with advanced atherosclerotic plaques. Life Sci. 2015;129:3–9. doi:10.1016/j.lfs.2014.10.010
   PubMed Web of Science ®Google Scholar
• De Santa F, Totaro MG, Prosperini E, Notarbartolo S, Testa G, Natoli G. The histone H3 lysine-27 demethylase Jmjd3 links inflammation to inhibition of polycomb-mediated gene silencing. Cell. 2007;130(6):1083–1094. doi:10.1016/j.cell.2007.08.019
   PubMed Web of Science ®Google Scholar
• Kim DI, Park MJ, Choi JH, et al. PRMT1 and PRMT4 regulate oxidative stress-induced retinal pigment epithelial cell damage in SIRT1-dependent and SIRT1-independent manners. Oxid Med Cell Longev. 2015;2015:617919. doi:10.1155/2015/617919
   PubMed Web of Science ®Google Scholar
• Duraisamy AJ, Mishra M, Kowluru RA. Crosstalk between histone and DNA methylation in regulation of retinal matrix metalloproteinase-9 in diabetes. Invest Ophthalmol Vis Sci. 2017;58(14):6440–6448. doi:10.1167/iovs.17-22706
   PubMed Web of Science ®Google Scholar
• Chen LF, Mu Y, Greene WC. Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB. EMBO J. 2002;21(23):6539–6548. doi:10.1093/emboj/cdf660
   PubMed Web of Science ®Google Scholar
• Kiernan R, Bres V, Ng RW, et al. Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65. J Biol Chem. 2003;278(4):2758–2766. doi:10.1074/jbc.M209572200
   PubMed Web of Science ®Google Scholar
• Miao F, Gonzalo IG, Lanting L, Natarajan R. In vivo chromatin remodeling events leading to inflammatory gene transcription under diabetic conditions. J Biol Chem. 2004;279(17):18091–18097. doi:10.1074/jbc.M311786200
   PubMed Web of Science ®Google Scholar
• Kadiyala CS, Zheng L, Du Y, et al. Acetylation of retinal histones in diabetes increases inflammatory proteins: effects of minocycline and manipulation of histone acetyltransferase (HAT) and histone deacetylase (HDAC). J Biol Chem. 2012;287(31):25869–25880. doi:10.1074/jbc.M112.375204
   PubMed Web of Science ®Google Scholar
• Lee HT, Oh S, Ro DH, Yoo H, Kwon YW. The key role of DNA methylation and histone acetylation in epigenetics of atherosclerosis. J Lipid Atheroscler. 2020;9(3):419–434. doi:10.12997/jla.2020.9.3.419
   PubMedGoogle Scholar
• Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care. 1996;19(3):257–267. doi:10.2337/diacare.19.3.257
   PubMed Web of Science ®Google Scholar
• Berthiaume M, Boufaied N, Moisan A, Gaudreau L. High levels of oxidative stress globally inhibit gene transcription and histone acetylation. DNA Cell Biol. 2006;25(2):124–134. doi:10.1089/dna.2006.25.124
   PubMed Web of Science ®Google Scholar
• Qi Y, Yao R, Zhang W, Cui Q. KAT1 triggers YTHDF2-mediated ITGB1 mRNA instability to alleviate the progression of diabetic retinopathy. Pharmacol Res. 2021;170:105713. doi:10.1016/j.phrs.2021.105713
   PubMed Web of Science ®Google Scholar
• Yasuda H, Ohashi A, Nishida S, et al. Exendin-4 induces extracellular-superoxide dismutase through histone H3 acetylation in human retinal endothelial cells. J Clin Biochem Nutr. 2016;59(3):174–181. doi:10.3164/jcbn.16-26
   PubMed Web of Science ®Google Scholar
• Beltrami C, Angelini TG, Emanueli C. Noncoding RNAs in diabetes vascular complications. J Mol Cell Cardiol. 2015;89(Pt A):42–50. doi:10.1016/j.yjmcc.2014.12.014
   PubMedGoogle Scholar
• Lucas T, Bonauer A, Dimmeler S. RNA therapeutics in cardiovascular disease. Circ Res. 2018;123(2):205–220. doi:10.1161/CIRCRESAHA.117.311311
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–297. doi:10.1016/S0092-8674(04)00045-5
   PubMed Web of Science ®Google Scholar
• Suh N, Blelloch R. Small RNAs in early mammalian development: from gametes to gastrulation. Development. 2011;138(9):1653–1661. doi:10.1242/dev.056234
   PubMed Web of Science ®Google Scholar
• Fu X, Dong B, Tian Y, et al. MicroRNA-26a regulates insulin sensitivity and metabolism of glucose and lipids. J Clin Invest. 2015;125(6):2497–2509. doi:10.1172/JCI75438
   PubMed Web of Science ®Google Scholar
• McArthur K, Feng B, Wu Y, Chen S, Chakrabarti S. MicroRNA-200b regulates vascular endothelial growth factor-mediated alterations in diabetic retinopathy. Diabetes. 2011;60(4):1314–1323. doi:10.2337/db10-1557
   PubMed Web of Science ®Google Scholar
• Feng B, Cao Y, Chen S, Chu X, Chu Y, Chakrabarti S. miR-200b mediates endothelial-to-mesenchymal transition in diabetic cardiomyopathy. Diabetes. 2016;65(3):768–779. doi:10.2337/db15-1033
   PubMed Web of Science ®Google Scholar
• Baldeon RL, Weigelt K, de Wit H, et al. Decreased serum level of miR-146a as sign of chronic inflammation in type 2 diabetic patients. PLoS One. 2014;9(12):e115209. doi:10.1371/journal.pone.0115209
   PubMed Web of Science ®Google Scholar
• Wang HJ, Huang YL, Shih YY, Wu HY, Peng CT, Lo WY. MicroRNA-146a decreases high glucose/thrombin-induced endothelial inflammation by inhibiting NAPDH oxidase 4 expression. Mediators Inflamm. 2014;2014:379537. doi:10.1155/2014/379537
   PubMed Web of Science ®Google Scholar
• Lo WY, Peng CT, Wang HJ. MicroRNA-146a-5p mediates high glucose-induced endothelial inflammation via targeting interleukin-1 receptor-associated kinase 1 expression. Front Physiol. 2017;8:551. doi:10.3389/fphys.2017.00551
   PubMed Web of Science ®Google Scholar
• Ye EA, Steinle JJ. miR-146a attenuates inflammatory pathways mediated by TLR4/NF-kappaB and TNFalpha to protect primary human retinal microvascular endothelial cells grown in high glucose. Mediators Inflamm. 2016;2016:3958453. doi:10.1155/2016/3958453
   PubMed Web of Science ®Google Scholar
• Wapinski O, Chang HY. Long noncoding RNAs and human disease. Trends Cell Biol. 2011;21(6):354–361. doi:10.1016/j.tcb.2011.04.001
   PubMed Web of Science ®Google Scholar
• Michalik KM, You X, Manavski Y, et al. Long noncoding RNA MALAT1 regulates endothelial cell function and vessel growth. Circ Res. 2014;114(9):1389–1397. doi:10.1161/CIRCRESAHA.114.303265
   PubMed Web of Science ®Google Scholar
• Zhao J, Li L, Peng L. MAPK1 up-regulates the expression of MALAT1 to promote the proliferation of cardiomyocytes through PI3K/AKT signaling pathway. Int J Clin Exp Pathol. 2015;8(12):15947–15953.
   PubMed Web of Science ®Google Scholar
• Li H, Zhao Q, Chang L, et al. LncRNA MALAT1 modulates ox-LDL induced EndMT through the Wnt/beta-catenin signaling pathway. Lipids Health Dis. 2019;18(1):62. doi:10.1186/s12944-019-1006-7
   PubMedGoogle Scholar
• Gong YP, Zhang YW, Su XQ, Gao HB. Inhibition of long noncoding RNA MALAT1 suppresses high glucose-induced apoptosis and inflammation in human umbilical vein endothelial cells by suppressing the NF-kappaB signaling pathway. Biochem Cell Biol. 2020;98(6):669–675. doi:10.1139/bcb-2019-0403
   PubMedGoogle Scholar
• Bayoumi AS, Aonuma T, Teoh JP, Tang YL, Kim IM. Circular noncoding RNAs as potential therapies and circulating biomarkers for cardiovascular diseases. Acta Pharmacol Sin. 2018;39(7):1100–1109. doi:10.1038/aps.2017.196
   PubMed Web of Science ®Google Scholar
• Bazan HA, Hatfield SA, Brug A, Brooks AJ, Lightell DJ Jr, Woods TC. Carotid plaque rupture is accompanied by an increase in the ratio of serum circR-284 to miR-221 levels. Circ Cardiovasc Genet. 2017;10(4). doi:10.1161/CIRCGENETICS.117.001720
   PubMedGoogle Scholar
• Zhu K, Hu X, Chen H, et al. Downregulation of circRNA DMNT3B contributes to diabetic retinal vascular dysfunction through targeting miR-20b-5p and BAMBI. EBioMedicine. 2019;49:341–353. doi:10.1016/j.ebiom.2019.10.004
   PubMed Web of Science ®Google Scholar
• Wang F, Zhang M. Circ_001209 aggravates diabetic retinal vascular dysfunction through regulating miR-15b-5p/COL12A1. J Transl Med. 2021;19(1):294. doi:10.1186/s12967-021-02949-5
   PubMed Web of Science ®Google Scholar
• Sabanayagam C, Xu D, Ting DSW, et al. A deep learning algorithm to detect chronic kidney disease from retinal photographs in community-based populations. Lancet Digit Health. 2020;2(6):e295–e302. doi:10.1016/S2589-7500(20)30063-7
   PubMedGoogle Scholar
• Cardoso CRL, Salles GC, Leite NC, Salles GF. Prognostic impact of carotid intima-media thickness and carotid plaques on the development of micro- and macrovascular complications in individuals with type 2 diabetes: the Rio de Janeiro type 2 diabetes cohort study. Cardiovasc Diabetol. 2019;18(1):2. doi:10.1186/s12933-019-0809-1
   PubMedGoogle Scholar
• Gimeno-Orna JA, Faure-Nogueras E, Castro-Alonso FJ, Boned-Juliani B. Ability of retinopathy to predict cardiovascular disease in patients with type 2 diabetes mellitus. Am J Cardiol. 2009;103(10):1364–1367. doi:10.1016/j.amjcard.2009.01.345
   PubMed Web of Science ®Google Scholar
• Garofolo M, Gualdani E, Giannarelli R, et al. Microvascular complications burden (nephropathy, retinopathy and peripheral polyneuropathy) affects risk of major vascular events and all-cause mortality in type 1 diabetes: a 10-year follow-up study. Cardiovasc Diabetol. 2019;18(1):159. doi:10.1186/s12933-019-0961-7
   PubMed Web of Science ®Google Scholar
• Farrah TE, Dhillon B, Keane PA, Webb DJ, Dhaun N. The eye, the kidney, and cardiovascular disease: old concepts, better tools, and new horizons. Kidney Int. 2020;98(2):323–342. doi:10.1016/j.kint.2020.01.039
   PubMed Web of Science ®Google Scholar
• Spaide RF, Fujimoto JG, Waheed NK, Sadda SR, Staurenghi G. Optical coherence tomography angiography. Prog Retin Eye Res. 2018;64:1–55. doi:10.1016/j.preteyeres.2017.11.003
   PubMed Web of Science ®Google Scholar
• Kashani AH, Chen CL, Gahm JK, et al. Optical coherence tomography angiography: a comprehensive review of current methods and clinical applications. Prog Retin Eye Res. 2017;60:66–100. doi:10.1016/j.preteyeres.2017.07.002
   PubMed Web of Science ®Google Scholar
• Couturier A, Mane V, Bonnin S, et al. Capillary plexus anomalies in diabetic retinopathy on optical coherence tomography angiography. Retina. 2015;35(11):2384–2391. doi:10.1097/IAE.0000000000000859
   PubMed Web of Science ®Google Scholar
• Hwang TS, Jia Y, Gao SS, et al. Optical coherence tomography angiography features of diabetic retinopathy. Retina. 2015;35(11):2371–2376. doi:10.1097/IAE.0000000000000716
   PubMed Web of Science ®Google Scholar
• Ho H, Cheung CY, Sabanayagam C, et al. Retinopathy signs improved prediction and reclassification of cardiovascular disease risk in diabetes: a prospective cohort study. Sci Rep. 2017;7:41492. doi:10.1038/srep41492
   PubMed Web of Science ®Google Scholar
• Ting DSW, Tan GSW, Agrawal R, et al. Optical coherence tomographic angiography in type 2 diabetes and diabetic retinopathy. JAMA Ophthalmol. 2017;135(4):306–312. doi:10.1001/jamaophthalmol.2016.5877
   PubMed Web of Science ®Google Scholar
• Yu DY, Cringle SJ, Yu PK, et al. Retinal capillary perfusion: spatial and temporal heterogeneity. Prog Retin Eye Res. 2019;70:23–54. doi:10.1016/j.preteyeres.2019.01.001
   PubMed Web of Science ®Google Scholar
• Lin AD, Lee AY, Zhang Q, et al. Association between OCT-based microangiography perfusion indices and diabetic retinopathy severity. Br J Ophthalmol. 2017;101(7):960–964. doi:10.1136/bjophthalmol-2016-309514
   PubMed Web of Science ®Google Scholar
• Durbin MK, An L, Shemonski ND, et al. Quantification of retinal microvascular density in optical coherence tomographic angiography images in diabetic retinopathy. JAMA Ophthalmol. 2017;135(4):370–376. doi:10.1001/jamaophthalmol.2017.0080
   PubMed Web of Science ®Google Scholar
• Kim AY, Chu Z, Shahidzadeh A, Wang RK, Puliafito CA, Kashani AH. Quantifying microvascular density and morphology in diabetic retinopathy using spectral-domain optical coherence tomography angiography. Invest Ophthalmol Vis Sci. 2016;57(9):OCT362–OCT370. doi:10.1167/iovs.15-18904
   PubMed Web of Science ®Google Scholar
• Zhang B, Chou Y, Zhao X, Yang J, Chen Y. Early detection of microvascular impairments with optical coherence tomography angiography in diabetic patients without clinical retinopathy: a meta-analysis. Am J Ophthalmol. 2021;222:226–237. doi:10.1016/j.ajo.2020.09.032
   PubMed Web of Science ®Google Scholar
• Park YG, Kim M, Roh YJ. Evaluation of foveal and parafoveal microvascular changes using optical coherence tomography angiography in type 2 diabetes patients without clinical diabetic retinopathy in South Korea. J Diabetes Res. 2020;2020:6210865. doi:10.1155/2020/6210865
   PubMed Web of Science ®Google Scholar
• Ehlers JP, Jiang AC, Boss JD, et al. Quantitative ultra-widefield angiography and diabetic retinopathy severity: an assessment of panretinal leakage index, ischemic index and microaneurysm count. Ophthalmology. 2019;126(11):1527–1532. doi:10.1016/j.ophtha.2019.05.034
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Sadeghipour A, Gerendas BS, Waldstein SM, Bogunovic H. Artificial intelligence in retina. Prog Retin Eye Res. 2018;67:1–29. doi:10.1016/j.preteyeres.2018.07.004
   PubMed Web of Science ®Google Scholar
• Poplin R, Varadarajan AV, Blumer K, et al. Prediction of cardiovascular risk factors from retinal fundus photographs via deep learning. Nat Biomed Eng. 2018;2(3):158–164. doi:10.1038/s41551-018-0195-0
   PubMed Web of Science ®Google Scholar
• Abramoff MD, Lavin PT, Birch M, Shah N, Folk JC. Pivotal trial of an autonomous AI-based diagnostic system for detection of diabetic retinopathy in primary care offices. NPJ Digit Med. 2018;1:39. doi:10.1038/s41746-018-0040-6
   PubMed Web of Science ®Google Scholar
• Behl T, Kotwani A. Exploring the various aspects of the pathological role of vascular endothelial growth factor (VEGF) in diabetic retinopathy. Pharmacol Res. 2015;99:137–148. doi:10.1016/j.phrs.2015.05.013
   PubMed Web of Science ®Google Scholar
• Ben-Av P, Crofford LJ, Wilder RL, Hla T. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Lett. 1995;372(1):83–87. doi:10.1016/0014-5793(95)00956-A
   PubMed Web of Science ®Google Scholar
• Genest J. C-reactive protein: risk factor, biomarker and/or therapeutic target? Can J Cardiol. 2010;26(Suppl A):41A–44A. doi:10.1016/S0828-282X(10)71061-8
   PubMedGoogle Scholar
• Jia ZT, Liu CY, Li H. Changes of the concentration of serum ischemia modified albumin and high sensitivity C-reactive protein in type 2 diabetic patients with retinopathy. Zhonghua Yan Ke Za Zhi. 2009;45(9):805–808.
   PubMedGoogle Scholar
• Aveleira CA, Lin CM, Abcouwer SF, Ambrosio AF, Antonetti DA. TNF-alpha signals through PKCzeta/NF-kappaB to alter the tight junction complex and increase retinal endothelial cell permeability. Diabetes. 2010;59(11):2872–2882. doi:10.2337/db09-1606
   PubMed Web of Science ®Google Scholar
• Gustavsson C, Agardh E, Bengtsson B, Agardh CD. TNF-alpha is an independent serum marker for proliferative retinopathy in type 1 diabetic patients. J Diabetes Complications. 2008;22(5):309–316. doi:10.1016/j.jdiacomp.2007.03.001
   PubMed Web of Science ®Google Scholar
• Shimizu E, Funatsu H, Yamashita H, Yamashita T, Hori S. Plasma level of interleukin-6 is an indicator for predicting diabetic macular edema. Jpn J Ophthalmol. 2002;46(1):78–83. doi:10.1016/S0021-5155(01)00452-X
   PubMed Web of Science ®Google Scholar
• Doganay S, Evereklioglu C, Er H, et al. Comparison of serum NO, TNF-alpha, IL-1beta, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus. Eye. 2002;16(2):163–170. doi:10.1038/sj/eye/6700095
   PubMed Web of Science ®Google Scholar
• Nguyen TT, Alibrahim E, Islam FM, et al. Inflammatory, hemostatic, and other novel biomarkers for diabetic retinopathy: the multi-ethnic study of atherosclerosis. Diabetes Care. 2009;32(9):1704–1709. doi:10.2337/dc09-0102
   PubMed Web of Science ®Google Scholar
• Demircan N, Safran BG, Soylu M, Ozcan AA, Sizmaz S. Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy. Eye. 2006;20(12):1366–1369. doi:10.1038/sj.eye.6702138
   PubMed Web of Science ®Google Scholar
• Murugeswari P, Shukla D, Rajendran A, Kim R, Namperumalsamy P, Muthukkaruppan V. Proinflammatory cytokines and angiogenic and anti-angiogenic factors in vitreous of patients with proliferative diabetic retinopathy and eales’ disease. Retina. 2008;28(6):817–824. doi:10.1097/IAE.0b013e31816576d5
   PubMed Web of Science ®Google Scholar
• Patel JI, Saleh GM, Hykin PG, Gregor ZJ, Cree IA. Concentration of haemodynamic and inflammatory related cytokines in diabetic retinopathy. Eye. 2008;22(2):223–228. doi:10.1038/sj.eye.6702584
   PubMed Web of Science ®Google Scholar
• Loporchio DF, Tam EK, Cho J, et al. Cytokine levels in human vitreous in proliferative diabetic retinopathy. Cells. 2021;10(5):1069. doi:10.3390/cells10051069
   PubMed Web of Science ®Google Scholar
• Hernandez C, Segura RM, Fonollosa A, Carrasco E, Francisco G, Simo R. Interleukin-8, monocyte chemoattractant protein-1 and IL-10 in the vitreous fluid of patients with proliferative diabetic retinopathy. Diabet Med. 2005;22(6):719–722. doi:10.1111/j.1464-5491.2005.01538.x
   PubMed Web of Science ®Google Scholar
• Feng S, Yu H, Yu Y, et al. Levels of inflammatory cytokines IL-1beta, IL-6, IL-8, IL-17A, and TNF-alpha in aqueous humour of patients with diabetic retinopathy. J Diabetes Res. 2018;2018:8546423. doi:10.1155/2018/8546423
   PubMed Web of Science ®Google Scholar
• Costagliola C, Romano V, De Tollis M, et al. TNF-alpha levels in tears: a novel biomarker to assess the degree of diabetic retinopathy. Mediators Inflamm. 2013;2013:629529. doi:10.1155/2013/629529
   PubMed Web of Science ®Google Scholar
• Khairul-Anwar I, Wan-Nazatul-Shima S, Siti-Lailatul-Akmar Z, Siti-Azrin AH, Zunaina E. Evaluation of TNF-alpha and IL-6 in saliva among diabetic retinopathy patients in East Coast Malaysia. Trop Med Int Health. 2022;27(3):310–316. doi:10.1111/tmi.13724
   PubMed Web of Science ®Google Scholar
• Wirostko B, Wong TY, Simo R. Vascular endothelial growth factor and diabetic complications. Prog Retin Eye Res. 2008;27(6):608–621. doi:10.1016/j.preteyeres.2008.09.002
   PubMed Web of Science ®Google Scholar
• Marumo T, Schini-Kerth VB, Busse R. Vascular endothelial growth factor activates nuclear factor-kappaB and induces monocyte chemoattractant protein-1 in bovine retinal endothelial cells. Diabetes. 1999;48(5):1131–1137. doi:10.2337/diabetes.48.5.1131
   PubMed Web of Science ®Google Scholar
• Kim I, Moon SO, Kim SH, Kim HJ, Koh YS, Koh GY. Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells. J Biol Chem. 2001;276(10):7614–7620. doi:10.1074/jbc.M009705200
   PubMed Web of Science ®Google Scholar
• Ahuja S, Saxena S, Akduman L, Meyer CH, Kruzliak P, Khanna VK. Serum vascular endothelial growth factor is a biomolecular biomarker of severity of diabetic retinopathy. Int J Retina Vitreous. 2019;5:29. doi:10.1186/s40942-019-0179-6
   PubMedGoogle Scholar
• Zhou Z, Ju H, Sun M, Chen H. Serum vascular endothelial growth factor levels correlate with severity of retinopathy in diabetic patients: a systematic review and meta-analysis. Dis Markers. 2019;2019:9401628. doi:10.1155/2019/9401628
   PubMed Web of Science ®Google Scholar
• Mitamura Y, Tashimo A, Nakamura Y, et al. Vitreous levels of placenta growth factor and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Diabetes Care. 2002;25(12):2352. doi:10.2337/diacare.25.12.2352
   PubMed Web of Science ®Google Scholar
• Ang WJ, Zunaina E, Norfadzillah AJ, et al. Evaluation of vascular endothelial growth factor levels in tears and serum among diabetic patients. PLoS One. 2019;14(8):e0221481. doi:10.1371/journal.pone.0221481
   PubMed Web of Science ®Google Scholar
• Lin Y, Xiao YC, Zhu H, et al. Serum fibroblast growth factor 21 levels are correlated with the severity of diabetic retinopathy. J Diabetes Res. 2014;2014:929756. doi:10.1155/2014/929756
   PubMed Web of Science ®Google Scholar